S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done

Ayala Pharmaceuticals (ADXS) Competitors

$0.67
0.00 (0.00%)
(As of 04/12/2024 ET)

ADXS vs. LGVN, TRVN, LIXT, AIMD, XBIO, PULM, ATXI, SHPH, GRAY, and PTIX

Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Longeveron (LGVN), Trevena (TRVN), Lixte Biotechnology (LIXT), Ainos (AIMD), Xenetic Biosciences (XBIO), Pulmatrix (PULM), Avenue Therapeutics (ATXI), Shuttle Pharmaceuticals (SHPH), Graybug Vision (GRAY), and Protagenic Therapeutics (PTIX). These companies are all part of the "pharmaceutical preparations" industry.

Ayala Pharmaceuticals vs.

Ayala Pharmaceuticals (NASDAQ:ADXS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Ayala Pharmaceuticals has higher revenue and earnings than Longeveron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$3.24M2.22N/AN/AN/A
Longeveron$709K5.99-$21.41M-$10.20-0.17

Longeveron has a consensus target price of $60.00, indicating a potential upside of 3,450.30%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Ayala Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ayala Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Longeveron
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Ayala Pharmaceuticals has a net margin of 0.00% compared to Longeveron's net margin of -3,020.17%. Longeveron's return on equity of -209.14% beat Ayala Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ayala PharmaceuticalsN/A -2,798.92% -195.41%
Longeveron -3,020.17%-209.14%-136.82%

Ayala Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 24.3% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Longeveron received 6 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 85.71% of users gave Longeveron an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Ayala PharmaceuticalsOutperform Votes
No Votes
Underperform Votes
34
100.00%
LongeveronOutperform Votes
6
85.71%
Underperform Votes
1
14.29%

In the previous week, Longeveron had 10 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 11 mentions for Longeveron and 1 mentions for Ayala Pharmaceuticals. Longeveron's average media sentiment score of 0.72 beat Ayala Pharmaceuticals' score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ayala Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Longeveron
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Longeveron beats Ayala Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADXS vs. The Competition

MetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.18M$6.46B$4.88B$7.64B
Dividend YieldN/A3.04%2.93%3.91%
P/E RatioN/A10.26211.2816.24
Price / Sales2.22331.732,409.0995.02
Price / CashN/A31.3836.8531.69
Price / Book-1.105.124.604.29
Net IncomeN/A$141.22M$104.37M$214.71M
7 Day Performance10.05%-2.35%-2.29%-2.30%
1 Month Performance-4.57%-3.46%-2.16%-1.58%
1 Year Performance-42.66%5.08%14.23%7.82%

Ayala Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGVN
Longeveron
3.0759 of 5 stars
$2.50
-9.1%
$60.00
+2,300.0%
-93.8%$6.91M$709,000.00-0.2523Insider Buying
Short Interest ↑
News Coverage
Gap Up
High Trading Volume
TRVN
Trevena
1.6864 of 5 stars
$0.38
+2.7%
$9.00
+2,268.4%
-48.3%$6.96M$3.12M-0.1235Short Interest ↑
Gap Up
LIXT
Lixte Biotechnology
0 of 5 stars
$3.10
-16.2%
N/A-49.6%$6.98MN/A-1.153Positive News
AIMD
Ainos
0 of 5 stars
$1.18
+2.6%
N/AN/A$7.02M$120,000.00-0.4646Short Interest ↓
XBIO
Xenetic Biosciences
0.9499 of 5 stars
$4.64
+5.7%
$40.00
+762.1%
-5.9%$7.15M$2.54M-1.694Short Interest ↓
News Coverage
Positive News
High Trading Volume
PULM
Pulmatrix
1.4785 of 5 stars
$1.81
+5.8%
$10.00
+452.5%
-20.3%$6.61M$7.30M-0.4728Short Interest ↑
Gap Up
ATXI
Avenue Therapeutics
0.8571 of 5 stars
$0.15
flat
N/A-88.1%$6.60MN/A-0.123Short Interest ↓
Gap Up
SHPH
Shuttle Pharmaceuticals
0 of 5 stars
$0.43
-2.3%
N/A-69.2%$7.18MN/A-0.997Gap Down
GRAY
Graybug Vision
0 of 5 stars
$4.19
+3.5%
N/A+99.5%$6.58MN/A-2.4227High Trading Volume
PTIX
Protagenic Therapeutics
0 of 5 stars
$1.64
-3.0%
N/A-13.8%$7.28MN/A-1.43N/AGap Down

Related Companies and Tools

This page (NASDAQ:ADXS) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners